DocumentRX-3465
Issued
Read3 min

FOLR1 ADC resensitizes colorectal tumors to anti-PD-1 in mice

An approved FOLR1 antibody-drug conjugate restored anti-PD-1 activity in resistant colorectal tumors in mice, linking FOLR1, STAT1 and MHC-I with a defined molecular mechanism.

TAG E-3628 · 624 words on the filing

Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice
Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in MiceKost9n4 / pixabay

Summary of findings

  • Only 15% of patients with colorectal cancer experience substantial benefit from treatments such as anti-PD-1.
  • Mirvetuximab soravtansine restored anti-tumor immunity and resensitized colorectal tumors to anti-PD-1 blockade in mice.
  • High FOLR1 expression predicted poor ICB response, enhanced cancer stemness and unfavorable patient outcomes.
  • FOLR1 stabilized AARS1, enabling STAT1 lactylation at K193, TCPTP interaction and STAT1 dephosphorylation at Y701.

By Olivia Hart

Only 15% of patients with colorectal cancer experience substantial benefit from immune checkpoint blockade treatments such as anti-PD-1, according to a new study. Colorectal cancer is the third most common cancer worldwide, and resistance to checkpoint blockade remains a central development problem.

The study, published in Science Translational Medicine under the title “Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer,” identifies folate receptor α (FOLR1) as a driver of immune evasion.

Mirvetuximab soravtansine, an approved FOLR1-targeting antibody-drug conjugate, restored anti-tumor immunity and resensitized colorectal tumors to anti-PD-1 blockade in mice. The reported combination efficacy came from mouse studies, while mechanistic findings also drew on in vitro experiments.

FOLR1 emerges as a resistance node

Researchers used fluorescence-activated cell sorting-based CRISPR activation screens with a druggable genome library and identified FOLR1 as a top negative regulator of immune checkpoint blockade, or ICB, response. The researchers said: “high expression of FOLR1 predicted a poor ICB response, enhanced cancer stemness, and unfavorable patient outcomes.”

Previous work had linked FOLR1 to more aggressive disease progression and poorer prognosis across several solid-tumor types. The new data place that association in an immunotherapy-resistance pathway. In colorectal tumors, defects in MHC-1 expression already impede antitumor immunity; loss of MHC-I antigen presentation drives immune evasion and resistance to immune checkpoint blockade.

Proteomic analysis supplied a molecular bridge. FOLR1 stabilized AARS1, or alanyl-tRNA synthetase 1, which acts as a lactyltransferase. AARS1 lactylated signal transducer and activator of transcription 1, or STAT1, at lysine-193, or K193. That modification facilitated STAT1 interaction with TCPTP, or T cell protein-tyrosine phosphatase, and induced STAT1 dephosphorylation at tyrosine-701, or Y701.

In vitro, FOLR1 indirectly impaired STAT1 signaling and dampened MHC-1 activity. That pathway supported cancer-cell adaptability and prevented CD8+ T cells from engaging tumor cells. The mechanism connects FOLR1 expression with an antigen-presentation defect that can blunt anti-PD-1 therapy.

Approved ADC reverses the phenotype

The team tested mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1. In the mouse experiments, the ADC restored anti-tumor immunity and resensitized colorectal tumors to anti-PD-1 blockade. The result paired FOLR1 inhibition with renewed checkpoint activity in resistant disease.

The authors wrote: “Our findings support anti-FOLR1 [antibody-drug conjugate] as a clinically actionable approach to overcome immune evasion and unlock immunotherapy efficacy in [colorectal cancer].”

No clinical efficacy or dosing results accompanied the finding, and the therapeutic conclusion remains preclinical. The study did, however, connect target expression, a specific signaling mechanism, resistance in vivo and an approved molecule already available for clinical use.

The authors suggest that integrating FOLR1-based treatments into existing regimens could improve outcomes in patients with treatment-resistant tumors. That proposal remains tied to the preclinical findings.

What does this change for colorectal cancer programs?

It gives developers a defined combination hypothesis: test FOLR1-directed treatment with anti-PD-1 in colorectal cancer selected for high FOLR1 expression and poor checkpoint response. High FOLR1 also marked greater cancer stemness and unfavorable patient outcomes, strengthening the case for expression-based patient selection.

For a portfolio team, the immediate asset is not another unvalidated pathway. It is a repurposing route around an approved ADC, backed by mechanistic evidence that FOLR1 sustains immune escape through AARS1-dependent STAT1 lactylation, MHC-1 suppression and CD8+ T-cell disengagement.

The next decision is whether the combination can reproduce the mouse result in patients and whether high FOLR1 provides a reliable selection marker. For now, the actionable conclusion is narrow: FOLR1 blockade merits clinical pairing with anti-PD-1, with patient efficacy as the decisive test.

via science.org (Original)

Share this article:

More from Olivia Hart

Olivia Hart

Show full bio

Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

13 articles

Linked filings

  1. V-7932
  2. K-9861
  3. P-9899
  4. C-4460
  5. V-1848

Next filing »